Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1875 1
1895 1
1920 1
1924 1
1925 1
1946 5
1947 7
1948 3
1949 2
1950 3
1951 4
1953 4
1954 3
1955 1
1956 3
1957 2
1958 9
1959 6
1960 10
1961 5
1962 6
1963 12
1964 9
1965 3
1966 14
1967 14
1968 17
1969 20
1970 8
1971 11
1972 9
1973 10
1974 15
1975 10
1976 16
1977 10
1978 18
1979 14
1980 14
1981 6
1982 14
1983 22
1984 15
1985 17
1986 17
1987 19
1988 15
1989 14
1990 18
1991 12
1992 17
1993 27
1994 16
1995 15
1996 23
1997 16
1998 22
1999 22
2000 12
2001 24
2002 33
2003 21
2004 25
2005 24
2006 15
2007 23
2008 27
2009 23
2010 23
2011 29
2012 22
2013 24
2014 26
2015 20
2016 26
2017 25
2018 33
2019 21
2020 31
2021 28
2022 36
2023 35
2024 25
2025 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,223 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial.
Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM, Ghamasaee P, Sareddy GR, Michalek J, Gilbert AR, Surapaneni P, Tiziani S, Pandey R, Chiou J, Lodi A, Floyd JR 2nd, Brenner AJ. Balinda HU, et al. Among authors: kelly wj. Nat Commun. 2024 Aug 7;15(1):6707. doi: 10.1038/s41467-024-50558-9. Nat Commun. 2024. PMID: 39112464 Free PMC article. Clinical Trial.
Neuroendocrine gene subsets are uniquely dysregulated in prostate adenocarcinoma.
Naranjo NM, Kennedy A, Testa A, Verrillo CE, Altieri AD, Kean R, Hooper DC, Yu J, Zhao J, Abinader O, Pickles MW, Hawkins A, Kelly WK, Mitra R, Languino LR. Naranjo NM, et al. Among authors: kelly wk. Cancer Biol Ther. 2024 Dec 31;25(1):2364433. doi: 10.1080/15384047.2024.2364433. Epub 2024 Jun 26. Cancer Biol Ther. 2024. PMID: 38926911 Free PMC article.
Overview of Prostate Cancer Genetic Testing.
Chandrasekar T, Kelly WK, Gomella LG. Chandrasekar T, et al. Among authors: kelly wk. Urol Clin North Am. 2021 Aug;48(3):279-282. doi: 10.1016/j.ucl.2021.04.002. Epub 2021 Jun 10. Urol Clin North Am. 2021. PMID: 34210484 Review. No abstract available.
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
Paller CJ, Zahurak ML, Mandl A, Metri NA, Lalji A, Heath E, Kelly WK, Hoimes C, Barata P, Taksey J, Garrison DA, Patra K, Milne GL, Anders NM, Nauroth JM, Durham JN, Marshall CH, Markowski MC, Eisenberger MA, Antonarakis ES, Carducci MA, Denmeade SR, Levine M. Paller CJ, et al. Among authors: kelly wk. Cancer Res Commun. 2024 Aug 1;4(8):2174-2182. doi: 10.1158/2767-9764.CRC-24-0225. Cancer Res Commun. 2024. PMID: 39076107 Free PMC article. Clinical Trial.
In Reply to Maholtz.
Andrews MA, Kelly WF, DeZee KJ. Andrews MA, et al. Among authors: kelly wf. Acad Med. 2019 Feb;94(2):153-154. doi: 10.1097/ACM.0000000000002527. Acad Med. 2019. PMID: 30694899 No abstract available.
Relevance of pRB Loss in Human Malignancies.
Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE. Mandigo AC, et al. Among authors: kelly wk. Clin Cancer Res. 2022 Jan 15;28(2):255-264. doi: 10.1158/1078-0432.CCR-21-1565. Epub 2021 Aug 18. Clin Cancer Res. 2022. PMID: 34407969 Free PMC article. Review.
PARP Inhibitors in Prostate Cancer.
Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK. Ramakrishnan Geethakumari P, et al. Among authors: kelly wk. Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2. Curr Treat Options Oncol. 2017. PMID: 28540598 Review.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: kelly w. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
1,223 results